Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 25-Apr-24 5:08 PM View:  | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 24-Apr-24 | Option Exercise | 20,020 | $17.26 | $345,618.00 | 2% 1.05M to 1.07M | |
| 02-Apr-24 4:15 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 31-Mar-24 | Grant | 79 | $69.20 | $5,466.80 | < 1% 9.61K to 9.69K | |
| 02-Apr-24 4:15 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 31-Mar-24 | Grant | 260 | $69.20 | $17,992.00 | < 1% 99.23K to 99.5K | |
| 22-Mar-24 4:12 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 20-Mar-24 | Option Exercise | 20,000 | $18.56 | $371,200.00 | 25% 79.23K to 99.23K | |
| 11-Mar-24 8:33 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 5,582 | $65.96 | $368,192.00 | (100%) 5.58K to 0 | |
| 11-Mar-24 8:31 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Planned Option Sale | 895 | $65.59 | $58,706.00 | (4%) 23.52K to 22.62K | |
| 11-Mar-24 8:33 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 20,565 | $65.21 | $1,341,120.00 | (2%) 1.07M to 1.05M | |
| 11-Mar-24 8:31 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 7,345 | $65.61 | $481,931.00 | (20%) 37.05K to 29.7K | |
| 11-Mar-24 8:31 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 2,817 | $65.59 | $184,776.00 | (12%) 22.62K to 19.8K | |
| 11-Mar-24 8:33 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Planned Option Sale | 4,539 | $65.96 | $299,395.00 | (45%) 10.12K to 5.58K | |
| 11-Mar-24 8:32 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 7,345 | $65.97 | $484,537.00 | (100%) 7.34K to 0 | |
| 11-Mar-24 8:32 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 7,345 | -- | -- | 100% 0 to 7.34K | |
| 11-Mar-24 8:33 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 20,565 | -- | -- | 2% 1.05M to 1.07M | |
| 11-Mar-24 8:31 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 7,345 | -- | -- | 25% 29.7K to 37.05K | |
| 11-Mar-24 8:31 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 7,345 | -- | -- | 45% 16.17K to 23.52K | |
| 11-Mar-24 8:33 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Planned Private Option Sale | 5,582 | $66.60 | $371,748.00 | (43%) 13.13K to 7.55K | |
| 11-Mar-24 8:32 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Planned Private Option Sale | 7,345 | $66.15 | $485,881.00 | (56%) 13.13K to 5.79K | |
| 11-Mar-24 8:33 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Sale (Planned) | 20,147 | $66.50 | $1,339,740.00 | (2%) 1.07M to 1.05M | |
| 11-Mar-24 8:31 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Sale (Planned) | 5,787 | $66.57 | $385,232.00 | (16%) 35.49K to 29.7K | |
| 11-Mar-24 8:33 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Sale (Planned) | 7,550 | $66.60 | $502,812.00 | (100%) 7.55K to 0 | |
| 11-Mar-24 8:32 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Sale (Planned) | 5,787 | $66.15 | $382,817.00 | (100%) 5.79K to 0 | |
| 11-Mar-24 8:33 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Planned Private Option Sale | 20,565 | $66.50 | $1,367,540.00 | (2%) 1.09M to 1.07M | |
| 11-Mar-24 8:31 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Planned Private Option Sale | 7,345 | $66.57 | $488,946.00 | (17%) 42.83K to 35.49K | |
| 11-Mar-24 8:31 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Planned Private Option Sale | 6,450 | $66.56 | $429,308.00 | (29%) 22.62K to 16.17K | |
| 08-Mar-24 5:58 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 06-Mar-24 | Option Exercise | 13,132 | -- | -- | 100% 0 to 13.13K | |
| 08-Mar-24 5:59 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 06-Mar-24 | Option Exercise | 40,712 | -- | -- | 4% 1.05M to 1.09M | |
| 08-Mar-24 5:59 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 06-Mar-24 | Option Exercise | 13,132 | -- | -- | 44% 29.7K to 42.83K | |
| 08-Mar-24 5:58 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 06-Mar-24 | Option Exercise | 13,132 | -- | -- | 138% 9.49K to 22.62K | |
| 08-Mar-24 5:58 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 06-Mar-24 | Option Exercise | 13,132 | -- | -- | 100% 0 to 13.13K | |
| 28-Feb-24 7:41 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 27-Feb-24 | Option Sale | 20,000 | $72.93 | $1,458,650.00 | (68%) 29.61K to 9.61K | |
| 28-Feb-24 7:41 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 27-Feb-24 | Option Exercise | 20,000 | $18.56 | $371,200.00 | 208% 9.61K to 29.61K | |
| 27-Feb-24 7:57 PM View: | Marcus Joel S Director | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Option Exercise | 36,757 | $48.93 | $1,798,680.00 | 94% 39.23K to 75.99K | |
| 27-Feb-24 7:59 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Planned Option Sale | 22,590 | $69.79 | $1,576,460.00 | (2%) 1.07M to 1.05M | |
| 27-Feb-24 7:58 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Planned Option Sale | 7,907 | $70.13 | $554,491.00 | (21%) 37.61K to 29.7K | |
| 27-Feb-24 7:58 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Planned Option Sale | 4,112 | $70.17 | $288,534.00 | (30%) 13.6K to 9.49K | |
| 27-Feb-24 8:00 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Option Exercise | 5,882 | $36.89 | $216,987.00 | 79% 7.46K to 13.34K | |
| 27-Feb-24 8:00 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Planned Option Sale | 13,337 | $69.43 | $925,961.00 | (100%) 13.34K to 0 | |
| 27-Feb-24 7:57 PM View: | Marcus Joel S Director | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Option Sale | 26,328 | $68.68 | $1,808,250.00 | (35%) 75.99K to 49.66K | |
| 27-Feb-24 8:00 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 26-Feb-24 | Planned Option Sale | 7,907 | $69.53 | $549,784.00 | (100%) 7.91K to 0 | |
| 27-Feb-24 7:59 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 23-Feb-24 | Option Exercise | 22,590 | -- | -- | 2% 1.05M to 1.07M | |
| 27-Feb-24 7:58 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 23-Feb-24 | Option Exercise | 7,907 | -- | -- | 27% 29.7K to 37.61K | |
| 27-Feb-24 7:58 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 23-Feb-24 | Option Exercise | 7,907 | -- | -- | 139% 5.69K to 13.6K | |
| 27-Feb-24 8:00 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 23-Feb-24 | Option Exercise | 7,455 | -- | -- | 100% 0 to 7.46K | |
| 27-Feb-24 8:00 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 23-Feb-24 | Option Exercise | 7,907 | -- | -- | 100% 0 to 7.91K | |
| 05-Feb-24 6:10 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 02-Feb-24 | Sale (Planned) | 33,885 | $67.07 | $2,272,690.00 | (3%) 1.08M to 1.05M | |
| 05-Feb-24 6:07 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 02-Feb-24 | Sale (Planned) | 11,860 | $67.15 | $796,367.00 | (29%) 41.56K to 29.7K | |
| 05-Feb-24 6:02 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 02-Feb-24 | Sale (Planned) | 6,167 | $67.19 | $414,355.00 | (52%) 11.86K to 5.69K | |
| 05-Feb-24 6:05 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 02-Feb-24 | Sale (Planned) | 11,183 | $66.62 | $745,037.00 | (100%) 11.18K to 0 | |
| 05-Feb-24 6:13 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 02-Feb-24 | Sale (Planned) | 11,860 | $66.42 | $787,719.00 | (100%) 11.86K to 0 | |
| 05-Feb-24 6:13 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 01-Feb-24 | Grant | 11,860 | -- | -- | 100% 0 to 11.86K |
